Keyphrases
Type I Diabetes
100%
Type 1 Diabetes Mellitus (T1DM)
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
41%
Sodium-glucose Cotransporter
30%
Risk Engine
28%
Steno
28%
Diabetic Ketoacidosis
26%
Albuminuria
23%
Cardiovascular Disease
21%
End-stage Kidney Disease
18%
Cardiovascular Risk
17%
Dapagliflozin
14%
Diabetes Management
11%
Hemoglobin A1c (HbA1c)
10%
Endothelial Glycocalyx
10%
Hospital Admission
10%
Perfused Boundary Region
10%
Register Study
10%
Danish Registers
10%
SpO2
10%
Oxygen Saturation
10%
Renal Risk Factors
10%
Time Trends
10%
Cardiorenal Risk
10%
Vascular Complications
10%
Realist Evaluation
10%
Kidney Disease
10%
Sotagliflozin
10%
Kidney Parameters
10%
Adjunct Therapy
10%
Randomized Placebo-controlled Trial
10%
Butyrate
10%
Renal Disease
10%
Inflammation Parameters
10%
Disease Risk
10%
Cardiorenal Protection
10%
Placebo
8%
Intestinal Inflammation
8%
Relative Change
8%
Incidence Rate
7%
Microvascular Disease
7%
Neuropathy
6%
Hypoglycemia
6%
Ketoacidosis
6%
Gastrointestinal Diseases
6%
Sodium-glucose Cotransporter Inhibitors
6%
Denmark
5%
Diabetes Complications
5%
Hypoxemia
5%
Health Score
5%
Medicine and Dentistry
Insulin Dependent Diabetes Mellitus
92%
Sodium Glucose Cotransporter 2 Inhibitor
52%
Cardiovascular Disease
36%
Diabetes
33%
Albuminuria
21%
Diabetic Ketoacidosis
21%
Nephropathy
20%
Placebo
16%
End Stage Renal Disease
15%
Dapagliflozin
13%
Chronic Kidney Disease
12%
Maturity Onset Diabetes of the Young
11%
Microvascular Complication
10%
Sotagliflozin
10%
Supplementation
10%
Sodium Glucose Cotransporter 1
10%
Glycocalyx
10%
Oxygen Saturation
10%
Adjuvant Therapy
10%
Butyric Acid
10%
Diabetes Mellitus
10%
Diabetic Nephropathy
10%
Base
10%
Synbiotic
10%
Probiotics
10%
Sodium Glucose Cotransporter 2
10%
Mineralocorticoid Antagonist
10%
Hypoglycemia
9%
Hemoglobin A1c
7%
Neuropathy
6%
Prebiotics
6%
Combination Therapy
6%
Ketoacidosis
6%
Enteritis
5%
Complications of Diabetes Mellitus
5%
Retinopathy
5%
Sodium Glucose Cotransporter Inhibitor
5%
Hypoxemia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Insulin Dependent Diabetes Mellitus
62%
Sodium Glucose Cotransporter 2 Inhibitor
51%
Diabetic Ketoacidosis
31%
Sodium Glucose Cotransporter 2
20%
Placebo
16%
Dapagliflozin
15%
Chronic Kidney Failure
12%
Kidney Disease
10%
Sotagliflozin
10%
Butyrate
10%
Cardiovascular Disease
10%
Sodium Glucose Cotransporter 1
10%
Inflammation
10%
Diabetes Mellitus
10%
Diabetic Nephropathy
10%
Base
10%
Cardiovascular Disease
10%
Mineralocorticoid Antagonist
10%
Non Insulin Dependent Diabetes Mellitus
8%
End Stage Renal Disease
8%
Hemoglobin A1c
7%
Combination Therapy
6%
Enteritis
5%
